Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Key trials in prostate cancer at ASCO 2022

Arun Azad • 27 May 2022
ASCO 2022
Genitourinary Cancer Prostate Cancer
ENZAMET TheraP VISION

Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Victoria, Australia, discusses which trials in prostate cancer to look out for at ASCO 2022, including TheraP (NCT03392428), VISION (NCT03511664), and ENZAMET (NCT02446405). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Arun Azad

4:02
Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: findings from clinical trials
Arun Azad • 23 Oct 2023
4:15
Non-WT BRCA associated with inferior prognosis in patients with metastatic prostate cancer
Arun Azad • 23 Oct 2023
1:56
TALAPRO-2: exposure efficacy of talazoparib and enzalutamide in mCRPC
Arun Azad • 23 Oct 2023
1:44
TALAPRO-2: exposure-safety of talazoparib + enzalutamide in mCRPC
Arun Azad • 23 Oct 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals